Similarly, pruritus has also been reported in NASH clinical trials using cilofexor, another nonsteroidal FXR agonist, and nidufexor, a partial FXR agonist, further indicating that pruritus induction is a class effect shared by FXR agonists [47,50–52]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.